Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis

Table 2 Longitudinal changes in CVD risk factors and RA disease activity according to treatment group

	csDMARDs			TNFi
	Baseline	12 months	P-value	Baseline	12 months	P-value
Cardiovascular disease risk factors
TGL	123 (68)	114 (50)	<0.001	113 (48)	106 (46)	0.023
LDL	122 (32)	112 (19)	<0.001	125 (26)	126 (30)	0.535
HDL	69 (12)	66 (10)	<0.001	74 (22)	74 (19)	0.609
TC	212 (3)	200 (19)	<0.001	221 (30)	218 (38)	0.161
SFG	88 (8)	85 (15)	<0.001	94 (13)	91 (11)	0.001
SBP	130 (19)	135 (19)	<0.001	136 (19)	135 (21)	0.152
DBP	80 (10)	83 (11)	<0.001	86 (10)	82 (10)	<0.001
BMI	25.5 (4.5)	25.5 (4.5)	0.442	25.6 (4.1)	25.6 (4.1)	0.226
Rheumatoid arthritis disease activity
ESR	20 (20)	16 (17)	<0.001	20 (17)	19 (14)	0.001
CRP	5.7 (8.2)	4.6 (8.7)	<0.001	2.40 (2.51)	2.49 (2.15)	0.410
CDAI	10 (10)	10 (10)	0.173	9 (7)	11 (10)	<0.001
DAS28	2.05 (1.35)	2.54 (1.36)	0.002	2.64 (0.77)	2.81 (1.23)	0.108

AoSI, aortic stiffness index; BMI, body mass index, CDAI, clinical disease activity score index; CRP, C-reactive protein; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; DAS28, disease activity score-28; DBP, diastolic blood pressure; ESR, erythrocyte sedimentation rate; HDL; high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; SFG, serum fasting glucose; TC, total cholesterol; TGL, triglycerides; TNFi, tumour necrosis factor inhibitors. All data reported as mean (standard deviation). P-value refers to paired samples t-test comparisons between values at baseline and 12 months

ISSN: 1478-6362